ANTI-CANCER AGENT COMPRISING HVJ-E AND CXCL2

• US 20180243355A1
• Filed: 08/23/2016
• Published: 08/30/2018
• Est. Priority Date: 08/24/2015
• Status: Active Grant

• Current Assignee: Immunomedicine Incorporated, Osaka University
• Original Assignee: Genomldea Incorporated, Osaka University
• Inventors: KANEDA, Yasufumi, NAKAJIMA, Toshihiro
• Granted Patent: US 10,441,613 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 35/76 Viruses; Subviral particles; Bacteriophages
• CPC Class Codes: A61K 38/19 Cytokines; Lymphokines; Interferons
• CPC Class Codes: A61K 38/195 Chemokines, e.g. RANTES
• CPC Class Codes: A61K 45/00 Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
• CPC Class Codes: C12N 2760/18871 Demonstrated in vivo effect
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2):

• (1) HVJ-E (hemagglutinating virus of Japan envelope),
• (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.

Claims

1-11. -11. (canceled)

12. A method for the prophylaxis or treatment of cancer, comprising administering an effective amount of a pharmaceutical composition comprising the following (1) and (2) to a subject:

(1) HVJ-E (hemagglutinating virus of Japan envelope),

(2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.

18. The method according to claim 12, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

19. The method according to claim 12, wherein the nucleic acid comprising the base sequence encoding CXCL2 is an expression vector comprising a base sequence encoding CXCL2.

20. The method according to claim 19, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

21. The method according to claim 19, wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E.

22. The method according to claim 21, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

23. The method according to claim 12, wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E.

24. The method according to claim 23, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

25. The method according to claim 12, wherein the CXCL2 expression inducing agent is selected from the group consisting of synthesized double stranded RNA, Lipopolysaccharide, leukotriene 4, platelet-activating factor (PAF), angiotensin II (Ang II), tumor necrosis factor-α

(TNF-α

) and Interleukin-17 (IL-17).

26. The method according to claim 25, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

27. The method according to claim 25, wherein the synthesized double stranded RNA is PolyI:

C.

28. The method according to claim 27, wherein the cancer is selected from the group consisting of melanoma, lung cancer, mesothelioma, tongue cancer, esophagus cancer, gastric cancer, liver cancer, large intestine cancer, prostate cancer, kidney cancer, bladder cancer, breast cancer, uterine cancer, ovarian cancer, brain tumor, thyroid cancer, angiosarcoma, osteosarcoma, chondrosarcoma, rhabdomyosarcoma and leiomyosarcoma.

13. A method of inducing an N1 type neutrophil, comprising administering an effective amount a pharmaceutical composition comprising the following (1) and (2) to a subject:

(1) HVJ-E (hemagglutinating virus of Japan envelope),

(2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.

29. The method according to claim 13, wherein the nucleic acid comprising a base sequence encoding CXCL2 is an expression vector comprising a base sequence encoding CXCL2.

30. The method according to claim 29, wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E.

31. The method according to claim 13, wherein the nucleic acid comprising a base sequence encoding CXCL2 is encapsulated in HVJ-E.

32. The method according to claim 13, wherein the CXCL2 expression inducing agent is selected from the group consisting of synthesized double stranded RNA, Lipopolysaccharide, leukotriene 4, platelet-activating factor (PAF), angiotensin II (Ang II), tumor necrosis factor-α

(TNF-α

) and Interleukin-17 (IL-17).

33. The method according to claim 32, wherein the synthesized double stranded RNA is PolyI:

C.

14-17. -17. (canceled)